Imaging Versus Cardiac Biomarker Monitored HER2 Directed Therapy in Patients With Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Due to a risk of heart failure during HER2 directed therapy in breast cancer, treatment is monitored with imaging of myocardial function, which is resource demanding for both patients and the health care system. The purpose of this study is to evaluate, if biomarkers can replace imaging based examinations of myocardial function during HER2 directed therapy.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Rak piersi HER2-dodatni bez przerzutów
- •Planowana standardowa chemioterapia i terapia skierowana na HER2 (trastuzumab +/- pertuzumab)
- •Wiek powyżej 18 lat
- •Prawidłowy rytm serca w EKG
- •Niska wartość białka NT-proBNP (poniżej 125 pg/ml)
- •Normalna wartość troponiny w krwi
- •Wystarczająca funkcja lewej komory serca (ponad 55%)
✗ Disqualifies
- •Przeciwwskazania do rezonansu magnetycznego serca
- •Przewlekła obturacyjna choroba płuc ze zmniejszonym wydychaniem poniżej 80% normy
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 90 Years
- Last updated (source)
- April 8, 2025
- Sex
- Female only
Therapies / drugs in trial
Locations (4)
Aalborg University Hospital
Aalborg, Denmark
Rigshospitalet
Copenhagen, Denmark
Herlev University Hospital
Herlev, Denmark
Odense University Hospital
Odense, Denmark
Trial contact
Ann Banke, MD, PHD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.